Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT07121946 is registered in ClinicalTrials.gov with LTZ Therapeutics, Inc. as lead sponsor.

NCT NCT07121946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07121946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Lead sponsor
LTZ Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 29, 2026
Completion date
February 29, 2028
Enrollment
42 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl - diffuse large b cell lymphoma, follicular lymphoma ( fl), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), non-hodgkin lymphoma refractory/ relapsed